Educational Development: Doseology Sciences Partners with McKinney for Regulatory Strategy Enhancement

### Enhancing Regulatory Strategy in Biotechnology: Doseology Sciences and McKinney Regulatory Science Advisors Forge Strategic Partnership

Doseology Sciences Inc. is making significant strides in the biotechnology sector through its recent partnership with McKinney Regulatory Science Advisors, announced on January 12, 2026. This collaboration focuses on refining Doseology's regulatory submission strategy, particularly in the burgeoning field of oral pouch technology. By leveraging McKinney's expertise as a premier FDA regulatory consulting firm, Doseology aims to enhance its formulation strategy, streamline data generation, and prepare comprehensive Pre-market Tobacco Product Applications (PMTAs) for both nicotine and innovative formulations. This move is pivotal for Doseology as it seeks to establish itself as a leader in delivering differentiated oral pouch products while ensuring consumer safety and regulatory compliance.

The partnership signifies a commitment to innovation and regulatory alignment, with Doseology's President & COO, Tim Corkum, emphasizing the company's focus on advancing safety and consistency in product dosing. McKinney will integrate its regulatory roadmap into Doseology's research and development processes, ensuring that all product designs and analytical testing adhere to stringent regulatory standards. With this collaboration, Doseology anticipates an accelerated pathway to market, allowing the company to navigate FDA requirements more effectively. This strategic initiative not only positions Doseology for commercial readiness but also enhances its competitive edge in the oral pouch market, which is becoming increasingly vital in the biotechnology landscape.

Furthermore, the partnership is set to bolster Doseology's intellectual property protection, which is crucial in the highly competitive biotechnology sector. By working closely with McKinney, Doseology is poised to refine its product portfolio and solidify its market presence. The integration of comprehensive PMTA readiness into its operational framework enhances the potential for successful market entry, offering a promising outlook for the company as it prepares to meet growing consumer demand for innovative oral pouch products. This strategic collaboration underscores the importance of regulatory foresight in bringing biotechnology products to market, ensuring that Doseology is well-equipped to address the challenges and opportunities within the industry.

In related developments, Enhanced Community Development, LLC has received a $65 million allocation from the U.S. Treasury Department's New Markets Tax Credit program, aimed at stimulating private investment in underserved communities. This funding will enable Enhanced Community Development to finance projects that enhance essential services and job creation, focusing on economic resilience in both urban and rural areas.

Additionally, Decoy Therapeutics, Inc. has announced a partnership with the Gates Foundation to expand global access to its peptide-conjugate antivirals, emphasizing the importance of developing flexible manufacturing platforms for emerging pathogens in low- and middle-income countries. This initiative highlights the critical role of innovation and collaboration in addressing public health challenges through advanced therapeutic solutions.